8-K: Tempus AI Reports Strong Q4 and Full Year 2024 Results, Forecasts Positive Adjusted EBITDA for 2025

Tempus AI announces impressive financial results for Q4 and full year 2024, highlighted by accelerated revenue and gross profit growth, and anticipates positive Adjusted EBITDA in 2025 following the acquisition of Ambry Genetics.

Summary

• Tempus AI reported a 35.8% year-over-year increase in revenue for the fourth quarter of 2024, reaching $200.7 million.
• The company's gross profit for the quarter increased by 49.7% to $122.1 million, driven by the Data and services segment.
• For the full year 2024, Tempus AI's revenue grew by 30.4% to $693.4 million.
• The company's annual gross profit increased to $381.1 million, representing a 33.2% year-over-year growth.
• Tempus AI ended the year with $940 million in Total Remaining Contract Value and a 140% net revenue retention rate.
• The company reported a net loss of ($13.0 million) for Q4 2024 and ($705.8 million) for the full year 2024, which included significant stock compensation expenses.
• Adjusted EBITDA improved to ($7.8 million) in Q4 2024 and ($104.7 million) for the full year 2024.
• Tempus AI completed the acquisition of Ambry Genetics on February 3, 2025.
• The company is increasing its revenue guidance to $1.24 billion for 2025 and expects full year 2025 Adjusted EBITDA of approximately $5 million.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, improved profitability metrics, and a clear path towards positive Adjusted EBITDA. The acquisition of Ambry Genetics further strengthens the company's position. However, the significant stock compensation expenses and past net losses temper the overall sentiment.

Positives

• Accelerated revenue growth in Q4 2024, reaching 35.8% year-over-year.
• Significant improvement in gross profit, with a 49.7% increase in Q4 2024.
• Strong performance in both Genomics and Data and services segments.
• High net revenue retention rate of 140%.
• Expected positive Adjusted EBITDA in 2025, marking a substantial improvement over 2024.
• Successful acquisition of Ambry Genetics, expanding the company's capabilities.
• National launch of the FDA-approved xT CDx with ADLT status and a reimbursement rate of $4,500 per test.
• CMS reimbursement for cardiac dysfunction assessments using the Tempus ECG-AF algorithm, currently paying $138/algorithm.
• Agreements for in-network provider status with major Blue Cross Blue Shield organizations.

Negatives

• The company reported a net loss of ($13.0 million) for Q4 2024 and ($705.8 million) for the full year 2024.
• Significant stock compensation expenses impacted the net loss, with $32.4 million in Q4 2024 and $547.7 million for the full year 2024.
• Adjusted EBITDA was still negative in 2024, although it showed improvement compared to the previous year.

Risks

• The company's forward-looking statements are subject to risks and uncertainties related to the intended use of Tempus products and services.
• Tempus faces risks related to its financial performance, ability to attract and retain customers and partners, and managing its growth and future expenses.
• Competition and new market entrants pose a risk to Tempus's market position.
• Compliance with new laws, regulations, and executive actions, including those related to artificial intelligence, could impact the company.
• The ability to maintain, protect, and enhance Tempus's intellectual property is crucial for its success.
• Tempus faces risks related to attracting and retaining qualified team members and key personnel.
• The company's ability to repay or refinance outstanding debt, or to access additional financing, is a risk factor.
• Future acquisitions, divestitures, or investments, including the integration of Ambry Genetics, carry inherent risks.
• Climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict could have adverse impacts.

Future Outlook

Tempus AI expects full year 2025 revenue of approximately $1.24 billion and Adjusted EBITDA of $5 million, representing approximately 79% annual growth and a $110 million improvement over 2024.

Management Comments

• Eric Lefkofsky, Founder and CEO of Tempus, stated that the company's performance in 2024 reflects the strength of its core businesses and the impact of its investments in AI.
• Management believes their investments in AI have positioned them well for the future, allowing them to make diagnostics intelligent and help patients live longer and healthier lives.
• Management remains on track to achieve key financial milestones, with expected robust revenue growth and positive Adjusted EBITDA in 2025.

Industry Context

Tempus AI's focus on AI-driven precision medicine aligns with the broader industry trend of leveraging technology to improve patient care and drug discovery. The acquisition of Ambry Genetics further strengthens its position in the genomics space, allowing it to offer a more comprehensive suite of services.

Comparison to Industry Standards

• Comparing Tempus AI to companies like Foundation Medicine (acquired by Roche) and Guardant Health, which also focus on genomic testing for cancer, Tempus's revenue growth rate of 30.4% for the full year 2024 is competitive.
• The expected Adjusted EBITDA of $5 million for 2025, if achieved, would be a significant milestone, as many companies in the precision medicine space are still working towards profitability.
• The $940 million in Total Remaining Contract Value indicates strong customer demand and future revenue potential, similar to the contract values reported by other leading diagnostic companies.

Stakeholder Impact

• Shareholders can expect potential value appreciation due to the company's strong growth and improved profitability.
• Employees may benefit from the company's continued success and expansion.
• Customers (physicians and patients) can expect improved precision medicine solutions and personalized patient care.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company as a more creditworthy borrower due to its improved financial performance.

Next Steps

• The company will hold a conference call and webcast on February 24, 2025, to discuss the financial results.
• Investors are encouraged to review the information on the company's investor relations website.

Key Dates

Keywords

Tempus AI, Financial Results, Precision Medicine, Artificial Intelligence, Genomics, Data and services, Adjusted EBITDA, Revenue Growth, Ambry Genetics, Healthcare